195 related articles for article (PubMed ID: 36350465)
1. Optimizing Safety Surveillance for COVID-19 Vaccines at the National Pharmacovigilance Centre Lareb: One Year of COVID-19 Vaccine Experience.
Oosterhuis I; Scholl J; van Puijenbroek E; Kant A; van Hunsel F
Drug Saf; 2023 Jan; 46(1):65-75. PubMed ID: 36350465
[TBL] [Abstract][Full Text] [Related]
2. Spontaneously reported adverse events following COVID-19 basic and booster immunizations in the Netherlands.
van der Boor SC; Schmitz-de Vries ETJ; Smits D; Scholl JHG; Rolfes L; van Hunsel F
Vaccine; 2023 Jun; 41(29):4319-4326. PubMed ID: 37286408
[TBL] [Abstract][Full Text] [Related]
3. Monitoring adverse events of the vaccination campaign against influenza A (H1N1) in the Netherlands.
van Puijenbroek EP; Broos N; van Grootheest K
Drug Saf; 2010 Dec; 33(12):1097-108. PubMed ID: 21077700
[TBL] [Abstract][Full Text] [Related]
4. Description of Frequencies of Reported Adverse Events Following Immunization Among Four Different COVID-19 Vaccine Brands.
Kant A; Jansen J; van Balveren L; van Hunsel F
Drug Saf; 2022 Apr; 45(4):319-331. PubMed ID: 35314943
[TBL] [Abstract][Full Text] [Related]
5. Capillary leak syndrome following COVID-19 vaccination: Data from the European pharmacovigilance database Eudravigilance.
Ruggiero R; Balzano N; Di Napoli R; Mascolo A; Berrino PM; Rafaniello C; Sportiello L; Rossi F; Capuano A
Front Immunol; 2022; 13():956825. PubMed ID: 36177033
[TBL] [Abstract][Full Text] [Related]
6. [Adverse events following immunization reported with COVID-19 vaccines in Burkina Faso: Analysis of spontaneous reports].
Sawadogo R; Ouoba J; Ilboudo D; Tchoumbi E; Lankoandé-Haro S; Fofana S; Sombié I; Samadoulougou S; Kirakoya-Samadoulougou F
Sante Publique; 2024 Feb; 35(6):149-159. PubMed ID: 38388395
[TBL] [Abstract][Full Text] [Related]
7. Observed-over-Expected analysis as additional method for pharmacovigilance signal detection in large-scaled spontaneous adverse event reporting.
van der Boom MDX; van Eekeren R; van Hunsel FPAM
Pharmacoepidemiol Drug Saf; 2023 Jul; 32(7):783-794. PubMed ID: 36919526
[TBL] [Abstract][Full Text] [Related]
8. COVID-19 mRNA Vaccines: A Retrospective Observational Pharmacovigilance Study.
Ferrara F; Mancaniello C; Varriale A; Sorrentino S; Zovi A; Nava E; Trama U; Boccellino M; Vitiello A
Clin Drug Investig; 2022 Dec; 42(12):1065-1074. PubMed ID: 36274082
[TBL] [Abstract][Full Text] [Related]
9. Impact of Covid-19 Vaccination on Spontaneous Pharmacovigilance Reporting in France.
de Germay S; Singier A; Salvo F; Pariente A;
Drug Saf; 2023 Dec; 46(12):1381-1389. PubMed ID: 37926785
[TBL] [Abstract][Full Text] [Related]
10. Maternal, fetal and neonatal outcomes among pregnant women receiving COVID-19 vaccination: The preg-co-vax study.
Mascolo A; di Mauro G; Fraenza F; Gaio M; Zinzi A; Pentella C; Rossi F; Capuano A; Sportiello L
Front Immunol; 2022; 13():965171. PubMed ID: 36263025
[TBL] [Abstract][Full Text] [Related]
11. Adverse events following immunisation (AEFI) reports from the Zimbabwe expanded programme on immunisation (ZEPI): an analysis of spontaneous reports in Vigibase® from 1997 to 2017.
Masuka JT; Khoza S
BMC Public Health; 2019 Aug; 19(1):1166. PubMed ID: 31455314
[TBL] [Abstract][Full Text] [Related]
12. Patterns of spontaneous reports on narcolepsy following administration of pandemic influenza vaccine; a case series of individual case safety reports in Eudravigilance.
Gadroen K; Straus SMJM; Pacurariu A; Weibel D; Kurz X; Sturkenboom MCJM
Vaccine; 2016 Sep; 34(41):4892-4897. PubMed ID: 27577558
[TBL] [Abstract][Full Text] [Related]
13. Optimizing Signal Management in a Vaccine Adverse Event Reporting System: A Proof-of-Concept with COVID-19 Vaccines Using Signs, Symptoms, and Natural Language Processing.
Dong G; Bate A; Haguinet F; Westman G; Dürlich L; Hviid A; Sessa M
Drug Saf; 2024 Feb; 47(2):173-182. PubMed ID: 38062261
[TBL] [Abstract][Full Text] [Related]
14. Numbers of spontaneous reports: How to use and interpret?
Kant A; van Hunsel F; van Puijenbroek E
Br J Clin Pharmacol; 2022 Mar; 88(3):1365-1368. PubMed ID: 34355808
[TBL] [Abstract][Full Text] [Related]
15. COVID-19 mRNA Vaccines Are Generally Safe in the Short Term: A Vaccine Vigilance Real-World Study Says.
Chen G; Li X; Sun M; Zhou Y; Yin M; Zhao B; Li X
Front Immunol; 2021; 12():669010. PubMed ID: 34093567
[TBL] [Abstract][Full Text] [Related]
16. Surveillance of adverse events following immunization related to human papillomavirus vaccines: 12 years of vaccinovigilance in Southern Italy.
Scavone C; Di Mauro C; Brusco S; Bertini M; di Mauro G; Rafaniello C; Sportiello L; Rossi F; Capuano A
Expert Opin Drug Saf; 2019 May; 18(5):427-433. PubMed ID: 30907147
[No Abstract] [Full Text] [Related]
17. Spontaneous reports of vaccination errors in the European regulatory database EudraVigilance: A descriptive study.
Hoeve CE; van Haren A; Sturkenboom MCJM; Straus SMJM
Vaccine; 2018 Dec; 36(52):7956-7964. PubMed ID: 30416019
[TBL] [Abstract][Full Text] [Related]
18. Leveraging COVID-19 Vaccine Safety Monitoring in Ethiopia and Pakistan to Enhance System-Wide Safety Surveillance.
Hagos AA; Sahile Z; Ahmed W; Phanouvong S
Glob Health Sci Pract; 2024 Feb; 12(Suppl 1):. PubMed ID: 38216210
[TBL] [Abstract][Full Text] [Related]
19. Barriers to COVID-19 vaccine surveillance: the issue of under-reporting adverse events.
Noh Y; Ko HY; Kim JH; Yoon D; Choe YJ; Choe SA; Jung J; Shin JY
Epidemiol Health; 2023; 45():e2023054. PubMed ID: 37309115
[TBL] [Abstract][Full Text] [Related]
20. Artificial Intelligence-Enabled Social Media Analysis for Pharmacovigilance of COVID-19 Vaccinations in the United Kingdom: Observational Study.
Hussain Z; Sheikh Z; Tahir A; Dashtipour K; Gogate M; Sheikh A; Hussain A
JMIR Public Health Surveill; 2022 May; 8(5):e32543. PubMed ID: 35144240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
